News & Updates
Filter by Specialty:
Lung ultrasound boosts accuracy of pneumonia diagnosis in ED
Lung ultrasound proves to be a useful tool for screening community-acquired pneumonia in the emergency department (ED), with a recent study showing that its use brings down diagnostic uncertainty from 73 percent to 14 percent.
Lung ultrasound boosts accuracy of pneumonia diagnosis in ED
30 Sep 2021Casirivimab-imdevimab combo may reduce hospitalization in mild-to-moderate COVID-19
Treatment with a combination of the recombinant human IgG1 monoclonal antibodies casirivimab and imdevimab reduced hospitalization rates in high-risk patients with mild-to-moderate COVID-19, according to results of a retrospective study.
Casirivimab-imdevimab combo may reduce hospitalization in mild-to-moderate COVID-19
29 Sep 2021Inhaled JAK inhibitor cuts exhaled nitric oxide in mild asthma
GDC-0214, an inhaled Janus kinase (JAK) inhibitor, induces dose-dependent reductions in fractional exhaled nitric oxide in patients with mild asthma, a recent study has found.
Inhaled JAK inhibitor cuts exhaled nitric oxide in mild asthma
29 Sep 2021Lung function not affected in children, adolescents post-COVID
COVID-19 does not appear to result in long-term impairment of lung function in children and adolescents, according to two studies presented at ERS 2021.
Lung function not affected in children, adolescents post-COVID
27 Sep 2021Educational intervention improves lung function, quality of life, inflammatory profile in asthmatics
An educational intervention for proper inhaled corticosteroid use helps improve lung function, quality of life, and control of inflammation among asthma patients, a recent study has found.
Educational intervention improves lung function, quality of life, inflammatory profile in asthmatics
26 Sep 2021Mepolizumab benefits held up over time
Beyond 1 year, the humanized monoclonal antibody mepolizumab maintained real-world efficacy and safety in patients with severe eosinophilic asthma in the REALITI-A cohort study, reports an expert at ERS 2021.
Mepolizumab benefits held up over time
25 Sep 2021Adding cyclophosphamide to glucocorticoids confers no survival benefit in IPF
Adding cyclophosphamide to glucocorticoid treatment in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was associated with a numerically increased risk of mortality, according to results of the phase III EXAFIP trial.